NMB Therapeutics
Developer and licensor of a nanoparticle-based nitric oxide delivery platform intended to enable controlled, sustained and tunable nitric-oxide (NO) bioavailability. The company partners with pharmaceutical and cosmeceutical firms to evaluate APIs, develop formulations and progress products from feasibility through preclinical evaluation and commercialization support across topical, inhalation, oral, IV and transmucosal routes.
Industries
Nr. of Employees
small (1-50)
NMB Therapeutics
395 Westubry Blvd., Hempstead, NY 11550, U.S.A.
Products
Nitric-oxide releasing nanoparticle delivery platform
A nanoparticle-based delivery system that encapsulates nitric-oxide donors and other actives to provide controlled and sustained NO release across multiple routes (topical, inhalation, oral, IV, transmucosal) and dosage forms.
Nitric-oxide releasing nanoparticle delivery platform
A nanoparticle-based delivery system that encapsulates nitric-oxide donors and other actives to provide controlled and sustained NO release across multiple routes (topical, inhalation, oral, IV, transmucosal) and dosage forms.
Services
Evaluate whether a partner's API is compatible with the nanoparticle platform and determine optimal product profiles in a cost-efficient and timely manner.
Collaborative development services from concept through product introduction including formulation development, preclinical testing support and commercialization planning.
Evaluate whether a partner's API is compatible with the nanoparticle platform and determine optimal product profiles in a cost-efficient and timely manner.
Collaborative development services from concept through product introduction including formulation development, preclinical testing support and commercialization planning.
Expertise Areas
- Nanoparticle drug delivery
- Topical and transdermal therapeutics
- Inhalation/aerosol drug delivery
- Wound healing therapeutics
Key Technologies
- Nitric oxide-releasing nanoparticles
- Sol-gel / hydrogel-glass composite formulations
- Nanoencapsulation for small molecules, peptides and antibodies
- Aerosolization into nanoscale droplets (inhaler delivery)
News & Updates
Abstract reporting porous organosilica microparticles containing nitrosylated thiol groups that generate NO and demonstrate dose-dependent bactericidal effects (5–9 log kill) against CRS isolates.
Abstract reporting NO-releasing nanoparticles that inhibited Trichophyton rubrum in vitro and cleared infection in a murine model with reduction of inflammatory cytokines.
Abstract describing a biocompatible nanoparticle platform combining glassy matrices and hydrogels to store and sustain release of NO upon hydration with tunable release profiles.
Abstract reporting porous organosilica microparticles containing nitrosylated thiol groups that generate NO and demonstrate dose-dependent bactericidal effects (5–9 log kill) against CRS isolates.
Abstract reporting NO-releasing nanoparticles that inhibited Trichophyton rubrum in vitro and cleared infection in a murine model with reduction of inflammatory cytokines.
Abstract describing a biocompatible nanoparticle platform combining glassy matrices and hydrogels to store and sustain release of NO upon hydration with tunable release profiles.